Evidence map›Paper›PMID 36987400›Full record

ArticleClinical, cosmetic and investigational dermatology2023

IncobotulinumtoxinA for the Treatment of Glabella and Forehead Dynamic Lines: A Real-Life Longitudinal Case Series.

Ana Lucia Gonzaga da Cunha, Rossana Vasconcelos, David Di Sessa, Gabriel Sampaio, Pitila Ramalhoto, Bruno F Zampieri, Bárbara S Deus, Suyan Vasconcelos, Talitha Bellote, Juiano Carvalho and 3 more

Abstract readCase Reports
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ana Lucia Gonzaga da CunhaClínica Skinline, Santo André, SP, Brazil.ORCID 0000-0001-8431-3386
Rossana VasconcelosNomina Clinica Médica De Cirurgia Plástica, Dermatologia e Oncologia, São Paulo, SP, Brazil.ORCID 0000-0002-6185-1840
David Di SessaDSL Clínica Médica, São Paulo, SP, Brazil.
Gabriel SampaioHost Clínica, São Paulo, SP, Brazil.
Pitila RamalhotoPrivate Clinic, Rio de Janeiro, RJ, Brazil.
Bruno F ZampieriHospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil.
Bárbara S DeusClinica Avatié, São Paulo, SP, Brazil.
Suyan VasconcelosClinica Splendore, Aracaju, SE, Brazil.
Talitha BelloteInstituto La Beautè, Curitiba, PR, Brazil.
Juiano CarvalhoPrivate Clinic, São Paulo, SP, Brazil.
Giseli PetronePrivate Clinic, Rio de Janeiro, RJ, Brazil.
Vinicius FigueredoHost Clinica, São Paulo, SP, Brazil.
Gustavo Limongi MoreiraDSL Clínica Médica, São Paulo, SP, Brazil.ORCID 0000-0001-9864-5277

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is substantial interpersonal variation in the patterns of muscular contraction that substantiates the use of personalized points of application and dosages in clinical practice to achieve optimal results. Nevertheless, there has been no real-life therapeutic series with botulinum toxin for aesthetic treatment of the face in which the subjects were systematically followed to assess its long-term benefit. Purpose: To assess the performance and length of the treatment of glabellar and forehead lines with IncobotulinumtoxinA in a real-life setting. Patients and Methods: We enrolled 20 adults with indications for the treatment of upper facial dynamic lines (glabella and forehead) with botulinum toxin. The protocols of injection points were personalized by the injectors. The participants were photographed under maximum facial contraction before the application (D0) and after 15, 90, 120, and 180 days. The photos were randomly assessed by two blinded experienced raters to consensually grade the dynamic lines according to the Merz Aesthetics Scales (MAS). Efficacy was defined as the reduction in the MAS score. Results: At D15, 18 (90%; 95% CI: 80%-100%) participants reached the zero score, or a 2-point reduction on the MAS score from the forehead and 16 (80%; 95% CI: 65-90%) reached that reduction for the glabella. These values from D90 were 14 (70%; 95% CI: 55-85%) for both sites. At D120, these values were 11 (55%; 95% CI: 35-75%) and 8 (40%; 95% CI: 25-55%) for the forehead and glabella. At D180, 10 (50%; 95% CI: 30-70%) participants presented a MAS score for forehead or glabella dynamic lines lower than the score assessed at D0. Conclusion: As much as 70% of the patients sustained a reduction of scores after 120 days of the treatment for dynamic glabellar and forehead lines. Half of the patients evidenced prolonged benefit at 180 days.

Indexed as

botulinum toxindynamic wrinklesincobotulinumtoxinAinjection techniqueONE21upper faceXeomin

Identifiers

PMID36987400
PMCPMC10040156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.